SCHEMBL4723666

SCHEMBL4723666

CCCCN(CC)c1ncncn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 7/20 0.42
HTT P42858 2/20 0.39
NCOA1 Q15788 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
MAPT P10636 4/20 0.35
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 2/20 0.35
DNM2 P50570 2/20 0.33
UTS2R Q9UKP6 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPK1 P28482 1/20 0.33
NPC1 O15118 1/20 0.32
TSHR P16473 1/20 0.32
RAB9A P51151 1/20 0.32
HPGD P15428 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18641556 0.92 DNM1 (0.40) CRHR1HTTNCOA1SMN1; SMN2NCOA3
SCHEMBL3182836 0.92 HTT (0.41) CRHR1HTTNCOA1SMN1; SMN2NCOA3
SCHEMBL4765553 0.88 SMN1; SMN2 (0.39) CRHR1HTTNCOA1SMN1; SMN2NCOA3
SCHEMBL4720589 0.88 HTT (0.36) CRHR1HTTSMN1; SMN2MAPTNPC1
SCHEMBL5824071 0.86 DNM1 (0.39) CRHR1HTTNCOA1SMN1; SMN2NCOA3
SCHEMBL29135407 0.84 DNM1 (0.43) CRHR1HTTNCOA1SMN1; SMN2NCOA3
SCHEMBL7236348 0.84 DNM1 (0.43) CRHR1HTTNCOA1SMN1; SMN2NCOA3
SCHEMBL16316871 0.83 CRHR1 (0.44) CRHR1HTTNCOA1SMN1; SMN2NCOA3
SCHEMBL4723956 0.83 TDP1 (0.37) HTTSMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL11541981 0.80 GBA1 (0.32) HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 CRHR1 3095/4885HTT 2486/4885NCOA1 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.